Alpha-1 Antitrypsin Deficiency Treatment Market Size, Share, Opportunities, And Trends By Treatment Type (Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy, Others), By Route Of Administration (Parenteral, Inhalation, Oral), By End-user (Speciality Clinics, Hospitals, Pharmacies, Others), And By Geography - Forecasts From 2024 To 2029

The Alpha-1 antitrypsin deficiency treatment market is anticipated to expand at a high CAGR over the forecast period.

The market for treatments for Alpha-1 Antitrypsin Deficiency (AATD) is expanding significantly due to improvements in therapeutic approaches and raised patient and healthcare professional awareness. Alpha-1 proteinase inhibitor intravenous infusions are used as augmentation therapy for AATD patients, which helps to reduce the disease's progression.

Furthermore, studies are being conducted to create new treatments, like gene therapy and small molecule medications, that try to more directly address the underlying genetic problem. The industry is distinguished by the existence of major businesses that concentrate on R&D projects to offer cutting-edge treatment alternatives. In the upcoming years, it is projected that rising global AATD prevalence and growing research spending will drive market expansion.

Market Drivers:

• Therapeutic innovations are anticipated to boost the Alpha-1 antitrypsin deficiency treatment market.

The market is expanding as a result of advancements in therapy for AATD, including gene therapies, enzyme replacements, and small molecule medications. These developments fill gaps in the medical field, provide new avenues for therapy, and improve patient outcomes. The goal of research and development is to expand the market by enhancing accessibility, safety, and efficacy. Innovative medicines are developed and commercialized more quickly when pharmaceutical corporations and academic institutions collaborate. These developments lead to a more comprehensive AATD treatment landscape, guaranteeing improved care for patients globally as awareness increases and diagnostic skills advance.

Boehringer Ingelheim declared in May 2022 that ArisGlobal had purchased their digital innovation, BRASS. This data insights engine will be integrated as LifeSphere Clarity into ArisGlobal's LifeSphere® technology platform, and it will be important in propelling the advancement of patient safety and pharmacovigilance across the board.

• Technological advancements are expected to boost the Alpha-1 antitrypsin deficiency treatment market.

Technological developments, including gene therapies, biomarker discovery, and genetic testing, are driving the market for treatments for AATD. These developments encourage the creation of novel medicines, enable earlier and more accurate diagnoses, and facilitate tailored treatment approaches. The efficacy and accessibility of medicines are also enhanced by developments in biotechnology and drug delivery technologies. The market for AATD treatments is growing thanks to technical advancements, which, when paired with favorable legislative frameworks and raised awareness, will eventually improve patient results and quality of life.

In response to CBS's request for proposals about the genetic deficit of Alpha-1 Antitrypsin, Takeda Canada Inc. and Canadian Blood Services have entered into a contract for GLASSIA. Glassia has been approved to be included with specified reimbursement requirements on the CBS Plasma Protein and Related Products formulary. By joining the Alpha-1 community in Canada, Takeda is demonstrating its continued dedication to creating cutting-edge therapies for uncommon illnesses.

• Rising disease burden is anticipated to boost the Alpha-1 antitrypsin deficiency treatment market.

The increasing number of people affected with AATD worldwide and the aging population are driving up the need for therapies. The market for treatments for Alpha-1 antitrypsin insufficiency is driven by the increasing number of cases of this illness, which also encourages more funding for R&D and innovation. Healthcare systems that prioritize the diagnosis and treatment of AATD are also driving market expansion through early detection campaigns and increased awareness.

As a result, government assistance and advocacy initiatives encourage pharmaceutical companies to develop innovative treatments, thus fostering the market's growth. Because of this, the market for AATD therapies keeps changing to accommodate the afflicted people's expanding healthcare requirements. Since AATD is a major risk factor for the onset and course of Chronic Obstructive Pulmonary Disease (COPD), it is recommended that all patients with adult-onset asthma or COPD undergo rigorous screening.

Additionally, According to research from the American Lung Association, males are more likely than women to die from COPD (36.7 against 31.5 per 100,000) in 2021, but more women than men die from the condition (72,727 versus 66,098)

Asia Pacific region is expected to grow significantly.

The market for treatments for AATD is growing significantly in the Asia-Pacific area due to rising disposable incomes, growing healthcare infrastructure, and rising awareness. More cases of AATD are being discovered as diagnostics and healthcare access expand throughout the region, which is driving up demand for treatments. The industry is expanding due to government initiatives aimed at addressing rare diseases and partnerships with global pharmaceutical corporations.

Furthermore, research and development breakthroughs are introducing new treatments specifically designed to meet the specific requirements of patients in this area. As a result, the Asia-Pacific market for AATD treatments is expected to continue expanding.

 Market Restraints:

• Limited availability of targeted therapies can constrain the market for Alpha-1 antitrypsin deficiency treatment.

The scarcity of tailored medicines is a significant obstacle in the market for treating AATD. Notwithstanding progress, there is still a deficiency of efficient therapies that can stop the spread of illness. Furthermore, many patients find it difficult to receive current medicines due to their high cost, especially in areas with inadequate healthcare resources. Furthermore, it can be difficult to effectively diagnose AATD due to its complexity. This can cause missing or delayed diagnosis, which makes it more difficult to start treatment and intervention on time.

Market Development:

• September 2023- Krystal Biotech, Inc., a commercial-stage biotechnology company, announced that the FDA in the United States has approved KB408's investigational new drug application (IND) for the treatment of AATD. The company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs.  
• October 2022- Awarded an extension of an existing tender by the Canadian Blood Services (CBS) for the supply of four IgG products, CYTOGAM®, HEPAGAM®, VARIZIG®, and WINRHO® SDF, with biopharmaceutical company Kamada Ltd., which focuses on specialized plasma-derived therapies, has been around for an extra three years, with an estimated total value of $22 million. This award ensures that sales of such products will continue on the Canadian market.

Market Segmentation:

• By Treatment Type
  • Augmentation Therapy
  • Bronchodilator
  • Corticosteroids
  • Oxygen Therapy
  • Others
• By Route of Administration
  • Parenteral
  • Inhalation
  • Oral
• By End-user
  • Speciality clinics
  • Hospitals
  • Pharmacies
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others